[Single versus multiple bypass grafts to each diseased coronary territory: impact on survival and major adverse cardiovascular and cerebrovascular events].

BACKGROUND: Complete revascularization is the gold standard of coronary artery bypass grafting (CABG). However, the rationale for revascularization of all diseased vessels is questionable. We aimed at evaluating the impact of multiple versus single grafts in each diseased coronary territory in the long-term survival and incidence of major adverse cardiac and cerebrovascular events (MACCE). METHODS: From January/00 to November/15, 5.694 consecutive patients were submitted to isolated CABG, of whom 4.243 (74.5%) had complete anatomical revascularization and constituted the study population. Patients were divided into two groups: multiple grafts to each major territory (RCA, LAD, Cx, n=755) a single graft to each territory (n=3.488). Mean follow-up time was 8.5±4.4 years and complete for 96.4% of patients. RESULTS: No differences were found concerning major immediate postoperative complications (cardiogenic shock, acute myocardial infarction or stroke) and thirty-day mortality was similar (0.7%; p=0.871). Long-term survival was 64.4±1.3% vs. 67.7±2.9%, p=0.232. Older age (HR:1.07; 1.06-1.08, p<0.001), diabetes mellitus (HR:1.44; 1.24-1-66, p<0.001), peripheral vascular disease (HR: 1.52; 1.29-1.81, p<0.001), chronic obstructive pulmonary disease (HR:1.38; 1.01-1.89, p=0.042), moderate/ severe cardiac dysfunction (HR:1.95; 1.60-2.38, p<0.001) and moderate/severe renal impairment (HR:1.65; 1.40-1.94, p<0.001) were independent predictors for late mortality. Freedom from MACCE was higher in multiple graft group (79.4±2.0% vs. 90.7±2.7%; p=0.026, respectively) at 4 years. CONCLUSION: Isolated CABG can be performed safely and with very low mortality. The number of bypass grafts did not adversely affect the perioperative results and long-term survival. However, implantation of multiple grafts was associated with lower incidence of major adverse events.

Introdução: A revascularização completa representa o gold standard para a cirurgia de revascularização miocárdica. No entanto, a pontagem de todas as artérias com doença significativa no mesmo território coronário é controversa. Deste modo, objetivamos avaliar o impacto, na sobrevivência a longo e na incidência de eventos cardio e cerebrovascular major (MACCE), da colocação de um enxerto único versus múltiplos enxertos coronários no mesmo território. Métodos: de Janeiro/00 a Novembro15, 5.694 doentes foram consecutivamente submetidos a CABG isolada, dos quais 4.243 (74.5%) tiveram revascularização anatómica completa, constituindo a população em estudo. Os doentes foram dividos em dois grupos: os que receberam enxertos múltiplos para cada território (CD, DA, CX, n=755) e os que receberam um enxerto único (n=3.488). O tempo médio de seguimento foi de 8.5±4.4 anos e completo em 96.4% dos doentes. Resultados: não foram observadas diferenças no que respeita às complicações major pós-operatórias (choque cardiogénico, enfarte agudo do miocárdio ou acidente vascular cerebral) bem como na mortalidade aos 30 dias (0.7%; p=0.871). A sobrevivência a longo prazo foi 64.4±1.3% vs. 67.7±2.9%, p=0.232. A idade avançada (HR:1.07; 1.06-1.08, p<0.001), diabetes (HR:1.44; 1.24-1-66, p<0.001), doença vascular periférica (HR:1.52; 1.29-1.81, p< 0.001), doença pulmonar crónica obstrutiva (HR:1.38; 1.01-1.89, p=0.042), disfunção cardíaca moderada/severa (HR:1.95; 1.60-2.38, p< 0.001) e disfunção renal moderada/severa (HR:1.65; 1.40-1.94, p< 0.001) foram preditores de mortalidade a longo prazo. A taxa livre de MACCE foi superior no grupo com múltiplos enxertos aos 4 anos (79.4±2.0% vs. 90.7±2.7%; p=0.026, respetivamente). Conclusão: a CABG é realizada com segurança e com baixa mortalidade. O número de enxertos não afetou os resultados perioperatorios e a sobrevivência a longo prazo. No entanto, a confecção de múltiplos enxertos foi associada a menor incidência de MACCE.

Heart transplantation: Early Results of Two Different Regimes of Immnunosuppression.

INTRODUCTION: The management of induction and maintenance immunosuppression therapy after heart transplantation (HT) remains a controversial issue. The dosage and the timing has been a changing target. We aimed at evaluate the incidence of acute cellular rejection (ACR) [≥1R grade], major infection and survival in first year after HT in patients receiving two different induction immunosuppression regimes and with a reduction in intensity of triple maintenance immunosuppression dose. METHODS: From November-2003 to June-2016, 317 patients were submitted to HT. After excluding those with pediatric age (n=8), those with previous renal or hepatic transplantation (n=2), those submitted to retransplantation (n=2), patients with early death without endomiocardial biopsy (n=10) and those in a transition maintenance regime (n=26), the study population resulted in 269 patients. These patients were divided in two groups: patients receiving the previous regime of two doses of basiliximab (group A, n=211) and those receiving a single dose of basiliximab (group B, n=58). All the patients were treated with a maintenance standard triple immunosuppressive regimen of corticosteroids, an inhibitor of calcineurin and mycophenolate mofetil but more immunosuppressive load in group A. RESULTS: Mean age of the recipients (group A vs. group B) was 54.6±10.6vs.55.0±9.8 years (p=0.808); 77.3%vs.75.9% were male (p=0.861); 28.4%vs.28.1% were diabetic (p=0.957); and ischemic etiology was present in 39.8%vs 41.0% of the patients (p=0.798), respectively. No differences were found, at first year, between the two groups concerning global ACR incidence (55.0%vs.56.9%, p=0.882, respectively) but major ACR (≥2R grade) was slightly superior in group B (16.6%vs.27.6%, p=0.080, respectively). Time-free from major ACR at 3rd, 6th and 12th months was, respectively 91.0±2.0%vs.84.5%±4.8%; 86.7±2.3%vs.74.1±5.7%; and 83.4±2.6%vs.72.4±5.9% (p=0.048). Time-free from major infection at 3rd, 6th and 12th months was, respectively 89.6±2.1%vs.82.8±5.0%; 87.7±2.3%vs.79.3±5.3%; and 84.4±2.5%vs.79.3±5.3% (p=0.253). No differences were found concerning survival at 3rd, 6th and 12th months (94.3±1.6%vs.94.8±2.9%; 92.4±1.8%vs.93.1±3.3%; and 90.0±2.1%vs.91.4±3.7%, (p=0.771) respectively). CONCLUSION: With this study, we verified that lowering doses of induction and maintenance therapy was responsible for increase cases of major ACR at first year of heart transplant. However, no differences were found concerning the incidence of major infection and early survival. Hence, effective immunosuppression induction regimen can apparently be done safely with a single dose regime without compromising survival at first year after HT.

Surgery on pancoast tumours. Casuistic of a cardiothoracic surgery center.

OBJECTIVES: The authors' objective is to report their experience in the treatment of this rare and challenging condition. METHODS: Retrospective study including all patients diagnosed with Pancoast tumour submitted to surgery, between April 2006 and July 2015. Data concerning the patients submitted to resection surgery with curative intent and statistical analysis. RESULTS: The sample consists of nine patients, five of which underwent diagnostic thoracoscopy and the other four, resection surgery with curative intent. The mean age was 61,5 ± 13.5 years, with predominance of the male gender (n=3). The most common presenting symptom was omalgia irradiating to the ipsilateral arm (n=3). Three patients underwent induction chemoradiotherapy (CRT) with tumour downstaging and all patients were submitted to superior lobectomy with en bloc resection of the invaded structures. The surgical approaches chosen where Dartevelle (n=2) and Shawn-Paulson (n=2). A complete resection was achieved in all patients and no cases of major complications and perioperative mortality were registered. Only non-small cell lung carcinomas (NSCLC) were registered. Two mortality cases were documented before the five years follow-up. CONCLUSIONS: The results obtained are accordant with those registered on the literature. Portuguese data on this matter are scarce and the authors hope that the publication of this article will raise awareness and enhance knowledge regarding the management of Pancoast tumours.